You are here:

AbbVie Ltd

Name SMC ID No Status Sub. Type
 
adalimumab (Humira) 858/13 Superseded Full submission
adalimumab (Humira) 1143/16 Accepted Full submission
adalimumab (Humira) 1173/16 Not Recommended Non submission
adalimumab (Humira) 1208/16 Not Recommended Non submission
adalimumab (Humira) 1050/15 Restricted Abbreviated Submission
adalimumab (Humira) 880/13 Restricted Abbreviated Submission
adalimumab (Humira) 881/13 Superseded Abbreviated Submission
adalimumab (Humira) 1243/17 Accepted Abbreviated Submission
adalimumab (Humira) 1068/15 Superseded Abbreviated Submission
adalimumab (Humira) 1209/16 Superseded Non submission
adalimumab (Humira) 1305/18 Not Recommended Non submission
co-careldopa (Duodopa) 316/06 Not Recommended Resubmission
co-careldopa-levodopa (Duodopa) 316/06 Restricted Resubmission
glecaprevir/pibrentasvir (Maviret) 1278/17 Accepted Full submission
lopinavir/ritonavir (Kaletra) 1302/18 Accepted Abbreviated Submission
ombitasvir / paritaprevir ritonavir (Viekirax) and dasabuvir (Exviera) 1051/15 Accepted Full submission
venetoclax (Venclyxto) 1249/17 Accepted Full submission

Back